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Purpose:  Nance-Horan  syndrome  is  typically  characterized  by  severe  bilateral  congenital  cataracts  and  dental
abnormalities. Truncating mutations in the Nance-Horan syndrome (NHS) gene cause this X-linked genetic disorder. NHS
encodes two isoforms, NHS-A and NHS-1A. The ocular lens expresses NHS-A, the epithelial and neuronal cell specific
isoform. The NHS-A protein localizes in the lens epithelium at the cellular periphery. The data to date suggest a role for
this isoform at cell-cell junctions in epithelial cells. This study aimed to identify the causative mutations in new patients
diagnosed with Nance-Horan syndrome and to investigate the effect of mutations on subcellular localization of the NHS-
A protein.
Methods: All coding exons of NHS were screened for mutations by polymerase chain reaction (PCR) and sequencing.
PCR-based mutagenesis was performed to introduce three independent mutations in the NHS-A cDNA. Expression and
localization of the mutant proteins was determined in mammalian epithelial cells.
Results: Truncating mutations were found in 6 out of 10 unrelated patients from four countries. Each of four patients
carried a novel mutation (R248X, P264fs, K1198fs, and I1302fs), and each of the two other patients carried two previously
reported mutations (R373X and R879X). No mutation was found in the gene in four patients. Two disease-causing
mutations (R134fs and R901X) and an artificial mutation (T1357fs) resulted in premature truncation of the NHS-A protein.
All three mutant proteins failed to localize to the cellular periphery in epithelial cells and instead were found in the
cytoplasm.
Conclusions: This study brings the total number of mutations identified in NHS to 18. The mislocalization of the mutant
NHS-A protein, revealed by mutation analysis, is expected to adversely affect cell-cell junctions in epithelial cells such
as the lens epithelium, which may explain cataractogenesis in Nance-Horan syndrome patients. Mutation analysis also
shed light on the significance of NHS-A regions for its localization and, hence, its function at epithelial cell junctions.
Nance-Horan  syndrome  (NHS;  OMIM  302350)  is
characterized  by  bilateral  congenital  cataracts,  dental
anomalies, craniofacial abnormalities, and, in some cases,
mental retardation and behavioral disturbance. This syndrome
is caused by mutations in the Nance-Horan syndrome (NHS)
gene located on Xp22.13 [1-3]. Additional features associated
with this disorder are microcornea and microphthalmia [4-6].
While the phenotype of the syndrome in males is severe and
necessitates cataract surgery early in life, females display
variable severity of cataract and dental defects [6,7]. Since
NHS  has  been  identified,  16  families  affected  with  this
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syndrome have been reported worldwide [3,8-11]. In these
families, 14 different mutations in four of the eight exons of
NHS  have  been  identified.  All  are  either  non-sense  or
frameshift mutations that would lead to premature truncation
of the protein.
NHS encodes two major isoforms, NHS-A and NHS-1A,
which are transcribed by alternate transcription start site usage
in exons 1 and 1A, respectively [12]. Individuals who are
carrying the disease-causing mutation, 400delC, in exon 1 of
the gene are predicted to affect the NHS-A isoform alone and
exhibit  typical  features  of  the  syndrome  [3,8].  The  Xcat
mouse,  a  model  for  NHS,  develops  X-linked  bilateral
congenital cataracts due to absence of the NHS-A isoform,
which resulted from an insertion mutation in intron 1 of NHS
[13].  Therefore,  disruption  of  the  NHS-A  isoform  seems
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1856primarily responsible for the syndrome. This epithelial and
neuronal cell-specific isoform is expressed in the human lens,
the organ severely affected in NHS, and the encoded protein
associates  with  the  peripheral  cell  membrane  in  the  lens
epithelium [12]. It co-localizes and interacts with the tight
junction protein, ZO (zonula occludens)-1, in epithelium ex
vivo, which suggests a role for this isoform at tight junctions
( [12] and unpublished data).
Herein, we report four novel and two recurrent mutations
in NHS in six unrelated NHS patients. To gain an insight into
the  functional  effects  of  various  NHS  mutations,  two
previously  reported  disease-causing  mutations  and  an
artificial  mutation  were  expressed  in  epithelial  cells,  and
localization of the mutant proteins was determined. While the
wild type NHS-A is associated with the cell membrane, the
mutant isoform proteins lost this ability, suggesting impaired
function as a consequence of protein mislocalization. The
present work reveals the significance of various regions of the
NHS-A protein for its localization.
METHODS
Subject recruitment and mutation analysis: The study adhered
to the tenets of the Declaration of Helsinki. DNA was obtained
from 10 individuals diagnosed with NHS or possible NHS by
the referring clinicians (R.V.J., Y.Y., F.B., L.V.M., and B.L.).
Where available, DNA from additional family members was
collected. Each coding exon and flanking splice site of NHS
was  amplified  by  polymerase  chain  reaction  (PCR)  using
intronic primers. Primer sequences and PCR conditions used
for each amplimer are given in Table 1. Due to their large size,
exon 1 was amplified as three overlapping fragments, exon 6
as eight overlapping fragments, and exon 8 as two. Amplified
PCR fragments were purified with the Wizard® SV Gel and
PCR  Clean-Up  System  (Promega  Corporation,  Sydney,
Australia). Cleaned fragments were directly sequenced using
BigDye Terminators (Applied Biosystems, Foster City, CA)
and  electrophoresed  on  an  ABI  3100  DNA  sequencer
(Applied  Biosystems).  Chromatograms  were  compared  to
each other and the reference sequence (GenBank accession
number  NM_198270)  using  Sequencher®  Software
(GeneCodes Corporation, Ann Arbor, MI).
Mutagenesis and recombinant DNA cloning: Mutant NHS-A
cDNA constructs were generated by PCR-based mutagenesis
and recombinant DNA cloning. Three mutations, 400delC
(exon 1), C2701T (exon 6), and 4071del299bp (exon 6), were
incorporated.  The  position  descriptions  of  the  latter  two
mutations take into consideration the alternatively spliced
exon 3a [12]. The wild type NHS-A cDNA including the exon
3a sequence was cloned in pCMV-Tag 2A (Stratagene, La
Jolla, CA) at EcoRI/SalI sites for use as the parent construct
for PCR-based mutagenesis. The sequences of mutagenesis
primers are listed in Table 2. The first round of PCR (PCR1
and PCR2) was performed on the parent construct. The primer
combinations used for incorporation of each mutation are
given in Table 3. PCR1 and PCR2 were performed with the
GC-RICH PCR system (Roche Diagnostics Australia Pty Ltd,
Castle Hill, NSW Australia) at 95 °C for 3 min, 95 °C for 30
s, at the annealing temperature specified for each primer pair
in Table 3 for 30 s, 68 °C for 45 s for 30 cycles, and 68 °C for
7 min. An equimolar mixture of PCR1 and PCR2 products
was used as the template for the second round of PCR (PCR3)
with the appropriate primer pair for incorporation of each
mutation (Table 3). PCR was performed as above except the
extension step lasted for 70 s. To replace the corresponding
region in the wild type cDNA, the resulting partial mutant
cDNAs were independently cloned into the parent construct
using restriction enzymes flanking the mutation site (Table 3).
The resulting FLAG epitope-tagged wild type and C2701T
and 4071del299bp mutant NHS-A cDNA were each excised
by NotI/PacI digestion and independently cloned in pQCXIN
(Clontech Laboratories Inc., Mountain View, CA) at the same
sites. The 400delC mutant cDNA (in pCMV-Tag 2A) was
digested with EcoRI and EcoRV, and the 1.3 kb digested
fragment carrying the mutation was cloned in pEGFP-C1 at
EcoRI/SmaI  sites  to  generate  a  GFP  (green  fluorescent
protein)-fusion construct. The generation of GFP-NHS-A was
described elsewhere [12].
Mammalian cell culture: HEK (human embryonic kidney)
293A and MDCK (Madin-Darby canine kidney) cells were
cultured in Dulbecco's modified Eagle's medium (DMEM;
GIBCO, Invitrogen Australia Pty Ltd, Victoria, Australia),
which was supplemented with 10% fetal bovine serum and
penicillin/streptomycin,  and  maintained  in  a  humidified
atmosphere at 37 °C and 5% CO2.
For the generation of MDCK cells stably expressing the
wild type and mutant proteins, 3×105 cells seeded per well in
a  six  well  plate  were  transfected  the  following  day  with
FLAG-tagged NHS-A, C2701T, or 4071del299bp constructs
(in pQCXIN) using Lipofectamine 2000 (Invitrogen Australia
Pty  Ltd)  according  to  the  manufacturer's  protocol.
Approximately 48 h after transfection, the cells were seeded
at 1:20 dilution and cultured in a selection medium containing
0.5 mg/ml G418 (Sigma-Aldrich Pty Ltd, Castle Hill, NSW
Australia).  Selection  was  continued  for  four  weeks  by
changing the selection medium every third day. The resulting
population  of  stable  transfectants  was  used  for  further
experiments.
Western blot analysis: 3×105 HEK 293A cells were seeded
per well in six well plates and transfected the following day
with wild type, mutant, or appropriate control plasmid using
Lipofectamine 2000. Approximately 48 h post-transfection,
the cells were harvested and cellular proteins extracted as
described elsewhere [12]. Total soluble proteins were size-
fractionated on a polyacrylamide gel by SDS–PAGE, and
western blot was prepared as previously described [12]. The
blot was probed with 1:500 dilution of mouse monoclonal
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1858anti-GFP antibody (Roche Diagnostics Australia Pty Ltd) or
1:1000 dilution of mouse monoclonal anti-FLAG tag antibody
(GenScript Corporation, Piscataway, NJ) and 1:1000 dilution
of sheep anti-mouse IgG-horseradish peroxidase secondary
antibody  (Chemicon  Australia  Pty  Ltd,  Boronia,  Victoria,
Australia). Antibody binding was detected with ECL western
blotting system (GE Healthcare Australia and New Zealand,
Sydney, Australia).
Protein localization: For localization of GFP-fusions, 3×105
MDCK cells were seeded onto glass coverslips in six well
plates. Cells were transfected the following day with GFP-
fusion  constructs  or  pEGFP-C1  control  (Clontech
Laboratories Inc.) using Lipofectamine 2000. Approximately
72  h  post-transfection,  the  cells  were  fixed  in  4%
paraformaldehyde/phosphate  buffered  saline  (PBS)  and
mounted on slides in buffered glycerol. Confocal microscopy
was performed on an Olympus AX70 microscope (Olympus
America Inc., Centre Valley, PA) attached to a Bio-Rad 1024
MRC scanning confocal system (Carl Zeiss Pty. Ltd., North
Ryde, Sydney, Australia) equipped with an Argon Ion and a
Helium neon laser using LaserSharp 2000 software. GFP was
excited with a 488 nm laser line and detected at 522 nm.
For localization of FLAG-tagged wild type and mutant
NHS-A proteins, 3×105 MDCK cells stably expressing the
protein were seeded onto glass coverslips in six well plates.
After culturing for four days, the cells were fixed in  4%
paraformaldehyde/PBS,  permeabilized  with  0.4%  Triton-
X100, blocked with 5% donkey serum, hybridized with mouse
monoclonal  anti-FLAG  tag  antibody  (1:1000;  GenScript
Corporation) and Alexa Fluor 488-conjugated anti-mouse IgG
antibody (1:250; Molecular Probes, Invitrogen Australia Pty
Ltd, Victoria, Australia), and mounted on slides in buffered
glycerol. Confocal microscopy was performed as explained
above.
RESULTS
DNA  samples  from  10  male  individuals  with  clinical
presentations consistent with Nance-Horan syndrome were
assessed for mutations in NHS. Table 4 shows the clinical
features of each patient and the mutation identified. All male
patients  presented  with  congenital  cataract,  and  female
carriers had sutural cataract. No mutations were identified in
individuals 102, 104, 124, and 134 despite features consistent
with  NHS.  Patient  102  had  X-linked  congenital  cataract.
Patient  124  appeared  to  display  the  NHS  phenotype,  but
TABLE 2. SEQUENCE OF PRIMERS USED FOR PCR-BASED MUTAGENESIS.
Primer Sequence
NHS-F01 5′-TACCGGAATTCTCCTTTCGCCAAGCGGATCGTGGAG
NHSA400R 5′-GCTGCCGGAGGGTACCGCCAGAGCGGCGTTGCTGA
NHSA400F 5′-ACGCCGCTCTGGCGGTACCCTCCGGCAGCTCTCGGACGT
NHSA1350R 5′-CAGCAATCAGAATATCCTCGGTTTGGCACTCAGAG
NHSA2220F 5′-TTTTAGTCCTGAGCGTCCCAAGGCAGACAG
NHSA2701R 5′-GGAAGATTGGCGTTTTGAATTCAAGAAGGCGTGTTGGCGA
NHSA2701F 5′-GCCAACACGCCTTCTTGAATTCAAAACGCCAATCTTCCCACCA
NHSA3050R 5′-AGCCACTTGATGGAGATGCCAAGCCAGCCA
NHSA4340F 5′-GCAGTCATTCACAGATCCAAGAGGAAAGTACTTG
NHSA4451R 5′-ACATTACTGCTGGGTGAAGAGATCTAACTGGCGCTGCTGCTGCTA
NHSA4451F 5′-CAGCAGCAGCGCCAGTTAGATCTCTTCACCCAGCAGTAATGTGAC
Tag2A810R 5′-TACGACTCACTATAGGGCGAATTGGGTACAC
TABLE 3. THE NHS-A MUTATIONS GENERATED BY PCR-BASED MUTAGENESIS.
Protein length in
amino acids
Mutation                   M wt. in kDa)
Primer pairs for PCR (annealing temperature °C) Restriction sites for
cloning PCR1 PCR2 PCR3
400delC R134fs) 195 (21.5) NHSF01 and
NHSA400R (56)
NHSA400F and
NHSA1350R (58)
NHSF01 and
NHSA1350R (65)
EcoRI/EcoRV
C2701T (R901X) 901 (99) NHSA2220F and
NHSA2701R (50)
NHSA2701F and
NHSA3050R (52)
NHSA2220F and
NHSA3050R (63)
HindIII/PmeI
4071del299bp T1357fs) 1367 (150) NHSA4340F and
NHSA4451R (56)
NHSA4451F and
Tag2A810R (56)
NHSA4340F and
Tag2A810R (62)
ScaI/SalI
The predicted size of each mutant protein is indicated. The primer combinations used for each round of PCR and the annealing
temperature for each primer set is given. The restriction enzyme sites used for the cloning of each partial mutant cDNA are
specified.
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1859characteristic screw-driver blade shaped incisors were not
present. Mutations were identified in the remaining six cases.
Individual  101,  a  19-year-old  male  from  Germany,
presented  with  major  ophthalmic  features  of  congenital
cataract and secondary glaucoma. He had microcornea and
nystagmus  at  three  months  of  age  and  presented  with
strabismus and microphthalmia in childhood. His mother had
nuclear cataract with cone-shaped sutural lens opacity. Both
the index case and his mother were found to have a previously
undescribed single base insertion 3596insA in exon 6, coding
for K1198 frameshift (Figure 1A). This mutation results in the
incorporation of four aberrant amino acids, terminating at
position 1203.
Patient 105 from Belgium had typical features of NHS
(congenital cataract, diastema, mental retardation, and large
ears). This patient was found to carry the C2635T mutation in
exon 6, encoding R879X (Figure 1B). This mutation was
previously reported in another family from the Netherlands
[10].
Individual 120 from Australia had typical features of
NHS.  His  mother  and  sister  also  had  cataract  and  dental
anomalies.  All  three  individuals  were  found  to  have  the
R373X mutation, which was previously reported by our group
in an unrelated isolated case of NHS from the UK as a de novo
mutation [3]. This mutation is designated at the DNA level by
C1117T (Figure 1C) and was also reported in a family from
the Netherlands [10].
The clinical features of Patient 122, an index case from
Israel, have been previously reported [14]. Prenatal diagnosis
of  cataract  in  the  male  fetus  of  the  proband’s  sister  (the
proband’s nephew) led the family to seek genetic diagnosis.
The  proband  displayed  many  typical  features  of  NHS.
Although there was early developmental delay, the patient
now has normal intelligence. The novel mutation, an 11 bp
deletion  at  position  3908  (3908delCATCTCAGTCA),  in
exon  6  causes  a  frameshift  (Figure  1D),  resulting  in  the
incorporation of four aberrant residues following I1302 and
terminating at position 1307. The proband’s mother and sister
are both carriers of the mutation and display a sutural cataract.
DNA was also obtained from the affected fetus and shown to
carry the same mutation.
Patients 127 and 135 were both referred from Sydney,
Australia. Each was found to have a different novel mutation
in exon 3 of NHS. Patient 127 had bilateral congenital cataract
diagnosed soon after birth as well as mild microphthalmia. At
15 months of age, the proband has small widely spaced teeth
and prominent ears. His mother and her monozygotic twin
sister  both  had  posterior  Y-sutural  cataracts  and  had
undergone  orthodontic  procedures  for  small  teeth  and
irregular crowns. The proband and both women were found
to have a single base deletion at position 792 (792delA; Figure
1E).  This  mutation  causes  a  frameshift  following  P264.
Eighteen aberrant amino acids are predicted to incorporate
into the protein that prematurely terminates at position 283.
The mutation was not identified in either of the proband’s
maternal grandparents, indicating that it arose de novo in his
mother and her twin sister.
Patient 135 was described as having both cataract and
microcornea. In addition, he had supernumerary maxillary
incisors and a high nasal bridge. His mother had bilateral
TABLE 4. CLINICAL FEATURES OF NHS PATIENTS TESTED.
Patient Ocular features Dental features MR FD Mutation Exon
101 Congenital Cataract
Microcornea
Microphthalmia Nystagmus
Strabismus
- No No K1198fs 6
102 Congenital Cataract - - - None
104 Congenital Cataract Unusual dentition Yes Yes None
105 Congenital Cataract Diastema Yes Large ears R879X 6
120 Congenital Cataract
Microphthalmia Glaucoma
Diastema Supernumerary
Screwdriver-blade shape
No Yes R373X 5
122 Congenital Cataract
Microphthalmia Strabismus
Supernumerary Abnormal
shape
Develop-mental
delay
Long thin face I1302fs 6
124 Congenital Cataract Supernumerary maxillary
incisors
Yes Large ears None
127 Congenital Cataract
Microphthalmia
Diastema No Prominent ears P264fs 3
134 Congenital Cataract
Microphthalmia
- - - None
135 Congenital Cataract
Microcornea
Supernumerary maxillary
incisors
No High nasal bridge R248X 3
The mutation identified in NHS  is shown at the protein level. Missing information is indicated by “-”. MR=mental retardation,
FD=facial dysmorphism, fs=frameshift mutation, K=lysine, R=arginine, I=isoleucine, P=proline, X=stop codon.
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1860sutural  cataracts.  A  previously  undescribed  truncating
mutation, C742T, was identified in both the proband and his
mother (Figure 1F). This mutation resulted in the premature
termination  of  translation  at  position  248  (R248X).  Fifty
chromosomes  from  normal  individuals  were  screened  as
controls and not found to carry any of the novel mutations
identified here in NHS patients.
To understand the effect of disease-causing mutations on
the  NHS-A  protein,  two  previously  reported  mutations,
400delC (R134fs) in exon 1 and C2635T (R879X) in exon 6
(named C2701T [R901X] in this study because the mutant
cDNA included the alternatively spliced exon 3a) [3,8,10],
and an artificial mutation, 4071del299bp (T1357fs), also in
exon 6 were created in the wild type cDNA by PCR-based
mutagenesis. The 400delC mutation was reported in a family
with typical features of NHS and is predicted to prematurely
truncate only the NHS-A protein isoform. The family with the
C2635T mutation displayed most features of the syndrome,
and the mutation would abolish the COOH-terminal half of
the NHS-A protein. The 4071del299bp mutant was obtained
as a cloning artifact while attempting to create the S1484X
artificial  mutation  in  exon  8.  While  cloning  the  PCR-
amplified  fragment  carrying  this  mutation  to  replace  the
corresponding wild type fragment, a 299 bp deletion was
incorporated due to star activity of ScaI, one of the restriction
enzymes  used  for  cloning.  The  resulting  4071del299bp
mutation is expected to give rise to a truncated NHS-A protein
very similar to that predicted to result from 3908del11bp
mutation identified here in patient 122 and was therefore
included in the study. The 400delC mutant was fused to GFP
at  the  NH2-terminus,  and  the  C2701T  and  4071del299bp
mutants were fused with a FLAG epitope tag. To confirm that
a  mutant  cDNA  expressed  the  truncated  protein,  it  was
transiently  expressed  in  HEK  293A  cells  and  protein
Figure 1. Chromatograms of identified mutations. In each case, the wild type sequence is shown above the mutated sequence for each patient.
A shows the 3596insA in patient 101; B shows the C2635T in patient 105; C shows the C1117T in patient 120; D shows the 3908del11bp in
patient 122; E shows the 792delA in patient 127; and F shows the C742T in patient 135.
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1861expression  determined  by  western  blotting.  A  truncated
protein of approximately 65 kDa was detected with an anti-
GFP antibody in cells expressing the 400delC mutant (Figure
2A). Similarly, around 140 and 225 kDa truncated proteins
were  revealed  with  an  anti-FLAG  tag  antibody  in  cells
respectively  expressing  the  C2701T  and  4071del299bp
mutants (Figure 2B). These protein sizes are greater than those
expected for each of the mutant proteins (Table 3). The wild
type NHS-A has a predicted size of 181 kDa but migrates
slower  than  its  expected  size  probably  due  to  post-
translational modification (Figure 2B) [12]. The greater than
expected  size  of  each  mutant  protein  observed  here  is
therefore not unusual and is also likely to result from post-
translational modification.
To  study  the  subcellular  distribution  of  the  mutant
proteins, GFP-NHS-A400delC was transiently expressed and
FLAG-tagged  C2701T  and  4071del299bp  mutants  stably
expressed  in  MDCK  epithelial  cells.  Localization  of  the
mutant proteins was compared with that of the wild type NHS-
A  protein.  Unlike  its  localization  to  the  peripheral  cell
membrane in lens epithelium in vivo, the NHS-A protein does
not associate with the cell membrane in lens epithelial cells
ex vivo because the latter do not form a polarized epithelium
in culture [12]. Therefore, localization studies were performed
in MDCK cells. As previously reported, transiently expressed
wild  type  GFP-NHS-A  primarily  localized  at  the  cellular
periphery in a punctate fashion in MDCK cells (Figure 3)
[12]. Cytoplasmic localization of the protein was seen in some
cells. GFP-NHS-A400delC mutant protein mainly distributed
in the cytoplasm and nucleus but was not found to associate
Figure 2. Expression of mutant NHS-A proteins in mammalian cells.
A: Lysates of HEK 293A cells transiently transfected with GFP-
NHS-A400delC and pEGFP-C1 constructs and untransfected cells
were  analyzed  by  western  blotting  with  anti-GFP  antibody.  B:
Lysates of HEK 293A cells transiently transfected with FLAG-NHS-
A,  FLAG-NHS-AC2701T  and  FLAG-NHS-A4071del299bp  in
pCMV-Tag 2A and untransfected cells were analyzed by western
blotting with anti-FLAG tag antibody. A protein band of greater than
150 kDa seen in all the lanes is due to non-specific binding of the
anti-FLAG tag antibody (indicated with an asterisk). A very faint
protein  band  of  approximately  130  kDa  in  the  NHS-A  and
4071Δ299bp lanes is most likely due to protein degradation. The
molecular  masses  of  proteins  standards  are  indicated.
UT=untransfected cells.
with the peripheral cell membrane (Figure 3). GFP, expressed
as a control, distributed both in the cytoplasm and nucleus.
Upon immunolabeling the FLAG-NHS-A stable transfectants
with an anti-FLAG tag antibody, intense immunoreactivity
was observed at the cell boundary in the majority of cells
(Figure 4). In some cells, immunoreactivity was also observed
in  the  cytoplasm.  In  stable  transfectants  of  FLAG-tagged
C2701T  and  4071del299bp  mutants,  FLAG  tag
immunolabeling was confined to the cytoplasm (Figure 4). No
immunoreactivity was observed at the cellular periphery in
cells expressing these mutants.
DISCUSSION
Here, we describe NHS mutations in six patients clinically
diagnosed with NHS. Four novel mutations (R248X, P264fs,
K1198fs,  and  I1302fs)  were  identified  in  four  of  these
patients.  The  other  two  (R373X  and  R879X)  represent
recurrent mutations and have been previously reported by us
and others [3,10]. This is the third report of the truncating
R373X mutation, and as such, this region of NHS could be a
mutation hot spot.
This  report  brings  the  total  number  of  known  NHS
mutations to 18, all of which are truncating mutations. All
known mutations are located in exons 1, 3, 5, and 6 with no
Figure 3. Localization of GFP-NHS-A400delC mutant in MDCK
cells.  Cells  were  transfected  with  GFP-NHS-A  and  GFP-NHS-
A400delC  fusion  constructs  and  pEGFP-C1  control.  Transiently
expressed fusion proteins were visualized by confocal microscopy.
GFP-NHS-A wild type protein primarily localized to the cellular
periphery whereas GFP-NHS-A400delC mutant protein localized in
the cytoplasm and nucleus. Apparent peripheral distribution of GFP
is  an  experimental  artifact  seen  only  between  some  adjoining
transfected cells. Images were taken with a 60X objective.
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1862obvious  phenotype/genotype  correlation.  The  apparent
absence of missense mutations in NHS is intriguing. It is
possible  that  missense  mutations  give  rise  to  a  different
(perhaps milder) phenotype such as isolated X-linked cataract
or X-linked mental retardation, although no reports of this
have  been  presented  to  date.  Ten  patients  with  a  clinical
diagnosis of NHS were screened for mutations in this study.
Mutations were identified in only 60% of patients. Patients
like 102 and 134 with only ophthalmic information available
and no identified mutation may not represent NHS cases. At
least one patient, 124, has all the features of the syndrome but
no identified mutation while other patients such as 127 and
135  with  superficially  similar  phenotypic  features  have  a
mutation in NHS. Thus, a clinical diagnosis is not always
significant in predicting a mutation in this gene. It is as yet
unknown if patients like 124 represent phenotypic overlap of
other  syndromes  with  NHS  or  if  mechanisms  other  than
protein truncating mutations in NHS can cause the phenotype.
Alternative mechanisms may include mutations in the introns
such as that present in the Xcat mouse or in the promoter or
5′ and 3′ untranslated regions of NHS, which have not been
investigated here due to the very large size of the gene and
Figure 4. Localization of FLAG-tagged wild type and mutant NHS-
A proteins in MDCK cells. MDCK cells stably expressing FLAG-
NHS-A, FLAG-NHS-AC2701T, and FLAG-NHS-A4071del299bp
proteins and untransfected cells were immunolabeled with an anti-
FLAG  tag  antibody,  and  labeling  was  detected  by  confocal
microscopy. Wild type FLAG-NHS-A protein mainly localized to
the cellular periphery whereas FLAG-NHS-AC2701T and FLAG-
NHS-A4071del299bp mutant proteins localized in the cytoplasm.
No non-specific immunoreactivity was observed in untransfected
cells. Representative images from four independent experiments are
shown. Images were taken with a 60X objective.
unidentified  regulatory  elements.  Patients  negative  for
mutations in the NHS gene in this study were not screened for
mutations in other genes.
The  two  disease-causing  mutations,  400delC  and
C2701T, and the artificial mutation, 4071del299bp, analyzed
here, respectively, reside in the NH2-terminus, middle, and
COOH-terminus of the NHS-A protein. All mutant proteins
lost the ability to associate with the cell membrane at the cell
boundary, which is exhibited by the wild type NHS-A protein
in epithelial cells, and instead localized in the cytoplasm. This
aberrant distribution of the mutant proteins may affect the
integrity of intercellular junctions in those epithelial cells that
express  NHS-A  such  as  the  anterior  lens  epithelium.
Interestingly, in an attempt to generate MDCK cells stably
expressing  the  FLAG-tagged  400delC  mutant  upon
immunolabeling with the anti-FLAG tag antibody, no positive
cells were detected after G418 selection (data not shown). We
speculate this may be due to the degradation of the mutant
protein. Hence, this protein was transiently expressed as a
GFP-fusion for localization studies. Nuclear localization of
GFP-NHS-A400delC  noted  here  might  be  due  to
overexpression of the fusion protein.
We  previously  reported  the  NH2-terminal  374  amino
acids of NHS-A to be responsible for its peripheral membrane-
associated localization in epithelial cells [12]. However, in
this study, the R134fs (400delC) mutant protein carrying the
first 134 residues localized in the cytoplasm (Figure 3). This
mislocalization of the mutant protein may be due to lack of
amino  acids  135-374.  However,  the  possibility  of
mislocalization due to the incorporation of aberrant amino
acids after the frameshift cannot be excluded. Cytoplasmic
localization of the truncated proteins, R901X (C2701T) and
T1357fs (4071del299bp), despite the presence of the NH2-
terminal  374  residues  may  be  due  to  protein  misfolding
(Figure 4). Both these truncated proteins lack the COOH-
terminal 295 amino acids from position 1358 to position 1652,
which may lead to their misfolding and hence mislocalization.
Because a GFP-fusion of the NH2-terminal 374 residues of
NHS-A associates with the cell membrane [12] but the R901X
and T1357fs mutant proteins do not, the downstream residues
in  these  proteins  may  interfere  with  their  folding  in  the
absence of the COOH-terminus. Taken together, these data
indicate the significance of three regions in the NHS-A protein
for  its  localization.  The  NH2-terminus  is  necessary  for
peripheral membrane associated localization of the protein
[12], the middle region causes mis-localization of the protein
in the absence of the COOH-terminus perhaps by exerting an
inhibitory  effect,  and  the  COOH-terminus  seems  to  be
important for proper localization of the protein probably by
facilitating its folding. Therefore, both the NH2- and COOH-
termini of the NHS-A protein are important for its peripheral
membrane-associated localization in epithelial cells and its
function at cell-cell junctions. In view of these findings, the
disease-causing mutations in NHS identified in NHS patients
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1863in  the  present  and  previous  studies  would  cause
mislocalization of the mutant NHS-A protein in epithelial
cells that express this isoform such as the lens epithelium.
Mislocalization of the protein may in turn impact epithelial
cell junctions in the developing lens and other organs affected
in this genetic disorder.
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